New infections caused by multidrug resistant bacteria is an increasing problem in both human and veterinary medicine.
We have recently developed efficient and stable bacteriocin-containing therapeutic formulations with
antibacterial effects on a range of pathogenic bacterial strains and their drug resistant derivatives . Our results show that in addition to be effective on antibiotic resistant bacteria our patented bacteriocins shows synergy with traditional antibiotics and other commercial bacteriocins, and even reduces resistance development compared to single
therapy. We have confirmed this in a mouse infection model which shows that the formulations effectively kill Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus pseudintermedius (MRSP) without the development of resistance, in contrast to other antibacterial treatments on the market. We will now identify potential customers and further develop our prototype formulations, including formulation with nanoparticles, and continue with efficiency studies in commercially relevant animal infection models. The overall goal of the project is to develop novel antimicrobial products based on our patented peptides, for effective treatment and prevention of topical infections in dogs and production animals like dairy cows. The primary customers are animal and human health companies developing antimicrobial products, while end users of our products will be farmers and veterinarians. During the project we aim to explore the commercial potential in more detail to identify new markets and customers of our products.